Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Heron Therapeutics, Inc. (HRTX : NSDQ)
 
 • Company Description   
Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.

Number of Employees: 128

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.34 Daily Weekly Monthly
20 Day Moving Average: 2,661,344 shares
Shares Outstanding: 189.85 (millions)
Market Capitalization: $65.29 (millions)
Beta: 1.61
52 Week High: $1.58
52 Week Low: $0.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.66% 3.12%
12 Week -14.90% -16.71%
Year To Date -73.55% -76.54%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
25 FENTON MAIN STREET SUITE 300
-
CARY,NC 27511
USA
ph: 858-251-4400
fax: 650-365-6490
ir@herontx.com http://www.herontx.com
 
 • General Corporate Information   
Officers
Craig Collard - Chief Executive Officer and Director
Adam Morgan - Chairman
Ira Duarte - Executive Vice President; Chief Financial Officer
Tom Cusack - Director
Sharmila Dissanaike - Director

Peer Information
Heron Therapeutics, Inc. (GSAC)
Heron Therapeutics, Inc. (CASIF)
Heron Therapeutics, Inc. (ALCD.)
Heron Therapeutics, Inc. (OMNN)
Heron Therapeutics, Inc. (CGPI.)
Heron Therapeutics, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 427746102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/03/26
Share - Related Items
Shares Outstanding: 189.85
Most Recent Split Date: 1.00 (0.05:1)
Beta: 1.61
Market Capitalization: $65.29 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/03/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 11.11
Price/Cash Flow: -
Price / Sales: 0.43
EPS Growth
vs. Year Ago Period: -50.00%
vs. Previous Quarter: 25.00%
Sales Growth
vs. Year Ago Period: 1.25%
vs. Previous Quarter: 8.51%
ROE
06/30/26 - -293.02
03/31/26 - -7,747.30
12/31/25 - -
ROA
06/30/26 - -10.00
03/31/26 - -8.94
12/31/25 - -4.62
Current Ratio
06/30/26 - 2.49
03/31/26 - 2.53
12/31/25 - 2.48
Quick Ratio
06/30/26 - 1.51
03/31/26 - 1.51
12/31/25 - 1.51
Operating Margin
06/30/26 - -16.60
03/31/26 - -14.59
12/31/25 - -7.25
Net Margin
06/30/26 - -22.52
03/31/26 - -20.53
12/31/25 - -13.04
Pre-Tax Margin
06/30/26 - -22.52
03/31/26 - -20.53
12/31/25 - -13.04
Book Value
06/30/26 - 0.03
03/31/26 - 0.04
12/31/25 - 0.07
Inventory Turnover
06/30/26 - 0.52
03/31/26 - 0.53
12/31/25 - 0.57
Debt-to-Equity
06/30/26 - 24.35
03/31/26 - 17.51
12/31/25 - 10.59
Debt-to-Capital
06/30/26 - 95.38
03/31/26 - 93.94
12/31/25 - 90.75
 

Powered by Zacks Investment Research ©